Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | THRA | P10827 | 3/20 | 0.44 |
| ▸ | THRB | P10828 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3909200 | 1.00 | S1PR1 (0.50) | S1PR1S1PR3S1PR4S1PR5HRH3 | |
| SCHEMBL6181254 | 0.88 | S1PR1 (0.57) | S1PR1S1PR3S1PR4S1PR5HRH3 | |
| SCHEMBL6179863 | 0.88 | S1PR1 (0.57) | S1PR1S1PR3S1PR4S1PR5HRH3 | |
| SCHEMBL6179864 | 0.78 | S1PR1 (0.48) | S1PR1S1PR3S1PR4S1PR5HRH3 | |
| SCHEMBL6362290 | 0.78 | S1PR1 (0.48) | S1PR1S1PR3S1PR4S1PR5HRH3 | |
| SCHEMBL4293459 | 0.76 | LMNA (0.54) | S1PR1S1PR3S1PR4S1PR5HRH3 | |
| SCHEMBL6199477 | 0.76 | S1PR1 (0.62) | S1PR1S1PR3S1PR4S1PR5HRH3 | |
| SCHEMBL23583415 | 0.76 | S1PR1 (0.55) | S1PR1S1PR3S1PR4S1PR5HRH3 | |
| SCHEMBL6676503 | 0.76 | S1PR1 (0.55) | S1PR1S1PR3S1PR4S1PR5HRH3 | |
| SCHEMBL5797072 | 0.75 | S1PR1 (0.60) | S1PR1S1PR3S1PR4S1PR5HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7479504-B2 | Edg receptor agonists | MERCK & CO., INC. (US) | 2009-01-20 | — | — | US | disclosed |
| US-20050033055-A1 | Edg receptor agonists | MERCK SHARP & DOHME CORP. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050033055-A1 | Edg receptor agonists | EDNRA, EDNRB, GPR65 | S1PR1 165/4885S1PR3 219/4885S1PR4 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.